Pediatric Annals

about the guest editor

Abstract

Lori Laffel, MD, MPH, is chief of the Pediatric, Adolescent, and Young Adult Section and an investigator in the Section on Genetics and Epidemiology at Joslin Diabetes Center in Boston, MA, and associate professor of pediatrics at Harvard Medical School.

Dr. Laffel is the principal investigator and program director of Joslin's National Institutes of Health (NEH) -funded postdoctoral fellowship and early career development training grants for pediatric endocrinologists entering the field of diabetes research. She also codirects the combined pediatric endocrine training program at Joslin and Children's Hospital Boston and continues to mentor numerous students and physicians-m-training. She serves as principal investigator on multiple NTH-funded, foundation-funded, and pharmaceutical clinical trials directed at improving the health of children and adolescents with type 1 and type 2 diabetes, including the TOD2AY Study (Treatment Options for Type 2 Diabetes in Adolescents and Youth) discussed in this issue.

Dr. Laffel has authored or co-authored more than 100 articles on diabetes. She has also been an invited speaker at multiple national and international meetings on pediatric diabetes and has served on national committees for the American Diabetes Association. She was recognized as a Woman of Valor by the American Diabetes Association in 2004.

Dr. Laffel's research and clinical interests focus on preventing the late complications of type 1 and type 2 diabetes and preserving the normal health, development, and quality of life of children, adolescents, and young adults with diabetes. She and her team have worked to identify risk factors for complications and they have developed and implemented innovative treatment programs aimed at optimizing diabetes control through the use of comprehensive multidisciplinary support programs, behavioral interventions, and new technologies.

Dr. Laffel received her medical degree from the University of Miami School of Medicine, Miami, FL, and her master's degree in public health from the Harvard School of Public Health. She completed her pediatric training at Children's Hospital Boston and her fellowship training at Children's Hospital Boston and at Joslin.…

Lori Laffel, MD, MPH, is chief of the Pediatric, Adolescent, and Young Adult Section and an investigator in the Section on Genetics and Epidemiology at Joslin Diabetes Center in Boston, MA, and associate professor of pediatrics at Harvard Medical School.

Dr. Laffel is the principal investigator and program director of Joslin's National Institutes of Health (NEH) -funded postdoctoral fellowship and early career development training grants for pediatric endocrinologists entering the field of diabetes research. She also codirects the combined pediatric endocrine training program at Joslin and Children's Hospital Boston and continues to mentor numerous students and physicians-m-training. She serves as principal investigator on multiple NTH-funded, foundation-funded, and pharmaceutical clinical trials directed at improving the health of children and adolescents with type 1 and type 2 diabetes, including the TOD2AY Study (Treatment Options for Type 2 Diabetes in Adolescents and Youth) discussed in this issue.

Dr. Laffel has authored or co-authored more than 100 articles on diabetes. She has also been an invited speaker at multiple national and international meetings on pediatric diabetes and has served on national committees for the American Diabetes Association. She was recognized as a Woman of Valor by the American Diabetes Association in 2004.

Dr. Laffel's research and clinical interests focus on preventing the late complications of type 1 and type 2 diabetes and preserving the normal health, development, and quality of life of children, adolescents, and young adults with diabetes. She and her team have worked to identify risk factors for complications and they have developed and implemented innovative treatment programs aimed at optimizing diabetes control through the use of comprehensive multidisciplinary support programs, behavioral interventions, and new technologies.

Dr. Laffel received her medical degree from the University of Miami School of Medicine, Miami, FL, and her master's degree in public health from the Harvard School of Public Health. She completed her pediatric training at Children's Hospital Boston and her fellowship training at Children's Hospital Boston and at Joslin.

10.3928/0090-4481-20050901-05

Sign up to receive

Journal E-contents